Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
Rheumatoid Arthritis
About this trial
This is an interventional other trial for Rheumatoid Arthritis
Eligibility Criteria
Inclusion Criteria:
- Healthy male and female (not of childbearing potential) participants as determined by medical and surgical history and assessments
- Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive
- Normal kidney function at screening
Exclusion Criteria:
- History of chronic headaches (eg, migraines, cluster headaches), defined as occurring 15 days or more a month, over the previous 3 months
- History of headaches related to caffeine withdrawal, including energy drinks
- History of syncope, orthostatic instability, or recurrent dizziness
Other protocol defined inclusion and exclusion criteria could apply
Sites / Locations
- PPD Development, LP
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Methotrexate
Cytochrome P450 and Transporter Substrates
Methotrexate single oral dose followed by leucovorin single oral dose on specified days followed by BMS-986195 coadministered with methotrexate single oral dose followed by leucovorin single oral dose on specified days
Caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days, BMS-986195 multiple oral dose administration on specified days, and BMS-986195 coadministered with caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin single oral dose on specified days.